c-Met/HGFR
Les inhibiteurs de c-Met/HGFR ciblent le Récepteur du Facteur de Croissance des Hépatocytes (c-Met), une tyrosine kinase impliquée dans des processus cellulaires tels que la croissance, la motilité et la morphogenèse. La signalisation de c-Met est impliquée dans la progression du cancer, la métastase et la résistance aux thérapies. Inhiber c-Met peut perturber la croissance et la propagation des tumeurs, faisant de ces inhibiteurs des outils précieux dans la recherche sur le cancer. Chez CymitQuimica, nous proposons des inhibiteurs de c-Met/HGFR pour soutenir vos recherches en oncologie, métastase et thérapies ciblées contre le cancer.
128 produits trouvés pour "c-Met/HGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Bozitinib
CAS :<p>Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.</p>Formule :C20H15F3N8Degré de pureté :99.16%Couleur et forme :SolidMasse moléculaire :424.38CSF1R-IN-2
CAS :<p>CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).</p>Formule :C20H20FN7O2Degré de pureté :99.29%Couleur et forme :SolidMasse moléculaire :409.42Onartuzumab
CAS :<p>Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.</p>Degré de pureté :97.3%Couleur et forme :LiquidMasse moléculaire :146.99 kDaPamufetinib
CAS :<p>Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.</p>Formule :C27H23FN4O4SDegré de pureté :99.39%Couleur et forme :SolidMasse moléculaire :518.56JNJ-38877618
CAS :<p>JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).</p>Formule :C20H12F2N6Degré de pureté :98.84% - 99.74%Couleur et forme :SolidMasse moléculaire :374.35c-Met inhibitor 1
CAS :<p>c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.</p>Formule :C17H14N8SDegré de pureté :98.77%Couleur et forme :SolidMasse moléculaire :362.41Emibetuzumab
CAS :<p>Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.</p>Degré de pureté :SDS-PAGE:96.2%;SEC-HPLC:98.8%Couleur et forme :LiquidMasse moléculaire :143.74 kDaRilotumumab
CAS :<p>Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.</p>Degré de pureté :SDS-PAGE:95% SEC-HPLC:97.51%Couleur et forme :LiquidMasse moléculaire :145.2 kDaPF-04217903 phenolsulfonate
CAS :<p>PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Formule :C25H22N8O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :546.56Fosgonimeton acetate
<p>Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).</p>Formule :C29H49N4O10PDegré de pureté :98.01%Couleur et forme :SolidMasse moléculaire :644.69Norleual
CAS :<p>Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.</p>Formule :C41H58N8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :774.95Antitumor agent-111
<p>Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.</p>Formule :C34H29ClF2N6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :675.08c-Met-IN-18
<p>C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.</p>Formule :C21H15FN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :374.371D228
<p>1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration of</p>Degré de pureté :98%Couleur et forme :Odour SolidNarnatumab
CAS :<p>Narnatumab (IMC-RON8) is a humanized antibody targeting the macrophage-stimulating receptor (RON) with antitumor activity, used in advanced malignant solid tumors research.</p>Degré de pureté :>95%Couleur et forme :LiquidTelisotuzumab
CAS :<p>Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.</p>Degré de pureté :SDS-PAGE:96.4%;SEC-HPLC:98.5%Couleur et forme :LiquidMasse moléculaire :145.50 kDaC-Met inhibitor D9
CAS :<p>C-Met inhibitor D9 is a c-Met kinase inhibitor.</p>Formule :C17H15N3O2Degré de pureté :97%Couleur et forme :SolidMasse moléculaire :293.32Umikibart
<p>Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.</p>Couleur et forme :Odour LiquidPROTAC c-Met degrader-1
CAS :<p>PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.</p>Formule :C45H41FN10O5Couleur et forme :SolidMasse moléculaire :820.87PROTAC c-Met degrader-3
<p>PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.</p>Formule :C51H54N10O7Couleur et forme :SolidMasse moléculaire :919.037c-Met-IN-23
<p>c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.</p>Formule :C16H13N7OMasse moléculaire :319.11816SU 5616
CAS :<p>SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.</p>Formule :C13H8ClNOSDegré de pureté :98.84%Couleur et forme :SoildMasse moléculaire :261.73BMS-777607
CAS :<p>BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.</p>Formule :C25H19ClF2N4O4Degré de pureté :98.16% - 98.56%Couleur et forme :SolidMasse moléculaire :512.89c-Met-IN-19
<p>c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549,</p>Formule :C34H37Cl2FN4O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :735.65LMTK3-IN-1
CAS :<p>Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.</p>Formule :C18H11F3N4ODegré de pureté :99.89%Couleur et forme :SoildMasse moléculaire :356.3c-Met-IN-17
<p>c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]</p>Formule :C21H15FN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :374.37SYN1143
CAS :<p>SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.</p>Formule :C31H29FN4O5Degré de pureté :99.69%Couleur et forme :SolidMasse moléculaire :556.58PF-04217903 methanesulfonate
CAS :<p>PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Formule :C20H20N8O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :468.49Merestinib dihydrochloride
CAS :<p>Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.</p>Formule :C30H24Cl2F2N6O3Couleur et forme :SolidMasse moléculaire :625.45Afatinib Dimaleate
CAS :<p>Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.</p>Formule :C32H33ClFN5O11Degré de pureté :98.11% - 99.87%Couleur et forme :SolidMasse moléculaire :718.08c-Kit-IN-1
CAS :<p>c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).</p>Formule :C26H21F2N5O3Degré de pureté :98.72% - 98.73%Couleur et forme :SolidMasse moléculaire :489.47X-376
CAS :<p>X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.</p>Formule :C25H25Cl2FN6O3Degré de pureté :97.87%Couleur et forme :SolidMasse moléculaire :547.41BMS817378
CAS :<p>BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).</p>Formule :C24H18ClF2N4O7PDegré de pureté :>99.99%Couleur et forme :SolidMasse moléculaire :578.85Ensartinib hydrochloride
CAS :<p>Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known</p>Formule :C26H29Cl4FN6O3Degré de pureté :98.73%Couleur et forme :SolidMasse moléculaire :634.36Glumetinib
CAS :<p>Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).</p>Formule :C21H17N9O2SDegré de pureté :99.79%Couleur et forme :SolidMasse moléculaire :459.48Hepln-13
CAS :<p>Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.</p>Formule :C17H13BrN2Degré de pureté :97.67%Couleur et forme :SolidMasse moléculaire :325.2Altiratinib
CAS :<p>Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,</p>Formule :C26H21F3N4O4Degré de pureté :99.67% - 99.75%Couleur et forme :SolidMasse moléculaire :510.46NVP-BVU972
CAS :<p>NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.</p>Formule :C20H16N6Degré de pureté :97.24% - >99.99%Couleur et forme :SolidMasse moléculaire :340.38BMS 777607
CAS :<p>BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.</p>Formule :C25H19ClF2N4O4Degré de pureté :98.30% - >99.99%Couleur et forme :SolidMasse moléculaire :512.89MK-8033
CAS :<p>MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).</p>Formule :C25H21N5O3SDegré de pureté :97.16%Couleur et forme :SolidMasse moléculaire :471.53Golvatinib
CAS :<p>Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor</p>Formule :C33H37F2N7O4Degré de pureté :98.24% - ≥95%Couleur et forme :SolidMasse moléculaire :633.69AMG-337
CAS :<p>AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).</p>Formule :C23H22FN7O3Degré de pureté :99.26% - 99.9%Couleur et forme :SolidMasse moléculaire :463.46Capmatinib 2HCl.H2O
CAS :<p>Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Formule :C23H21Cl2FN6O2Degré de pureté :99.77%Couleur et forme :SolidMasse moléculaire :503.36Foretinib
CAS :<p>Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.</p>Formule :C34H34F2N4O6Degré de pureté :98.07% - 99.68%Couleur et forme :SolidMasse moléculaire :632.65Ningetinib
CAS :<p>Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Formule :C31H29FN4O5Degré de pureté :99.95% - 99.98%Couleur et forme :SolidMasse moléculaire :556.58Crizotinib hydrochloride
CAS :<p>Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)</p>Formule :C21H23Cl3FN5ODegré de pureté :98.73% - 98.87%Couleur et forme :SolidMasse moléculaire :486.8Tivantinib
CAS :<p>Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.</p>Formule :C23H19N3O2Degré de pureté :98% - 99.41%Couleur et forme :SolidMasse moléculaire :369.42NPS-1034
CAS :<p>NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.</p>Formule :C31H23F2N5O3Degré de pureté :98.48%Couleur et forme :SolidMasse moléculaire :551.54CEP-40783
CAS :<p>CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).</p>Formule :C31H26F2N4O6Degré de pureté :99.76% - 99.84%Couleur et forme :SolidMasse moléculaire :588.56Ningetinib Tosylate
CAS :<p>Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Formule :C38H37FN4O8SDegré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :728.79Crizotinib
CAS :<p>Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.</p>Formule :C21H22Cl2FN5ODegré de pureté :99% - 99.87%Couleur et forme :SolidMasse moléculaire :450.34AMG-208
CAS :<p>AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.</p>Formule :C22H17N5O2Degré de pureté :98.56%Couleur et forme :SolidMasse moléculaire :383.4S49076
CAS :<p>S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.</p>Formule :C22H22N4O4SDegré de pureté :95.35% - 97.4%Couleur et forme :SolidMasse moléculaire :438.5DS-1205
CAS :<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Formule :C41H42FN5O7Degré de pureté :99.75%Couleur et forme :SolidMasse moléculaire :735.8Capmatinib 2HCl
CAS :<p>Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.</p>Formule :C23H19Cl2FN6ODegré de pureté :98.80%Couleur et forme :SolidMasse moléculaire :485.34SGX-523
CAS :<p>SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.</p>Formule :C18H13N7SDegré de pureté :99% - >99.99%Couleur et forme :SolidMasse moléculaire :359.41BMS-794833
CAS :<p>BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.</p>Formule :C23H15ClF2N4O3Degré de pureté :98% - 99.69%Couleur et forme :SolidMasse moléculaire :468.84XL092
CAS :<p>XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.</p>Formule :C29H25FN4O5Degré de pureté :98.60%Couleur et forme :SolidMasse moléculaire :528.53SCR-1481B1
CAS :<p>SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor</p>Formule :C32H40ClF2N6O13PDegré de pureté :98.07%Couleur et forme :SolidMasse moléculaire :821.12Amuvatinib
CAS :<p>Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.</p>Formule :C23H21N5O3SDegré de pureté :99.38% - >99.99%Couleur et forme :SolidMasse moléculaire :447.51PHA-665752
CAS :<p>PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.</p>Formule :C32H34Cl2N4O4SDegré de pureté :97.05% - 98.82%Couleur et forme :SolidMasse moléculaire :641.61Capmatinib
CAS :<p>Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Formule :C23H17FN6ODegré de pureté :99.24%Couleur et forme :SolidMasse moléculaire :412.42PF-04217903
CAS :<p>MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.</p>Formule :C19H16N8ODegré de pureté :98.41% - 98.55%Couleur et forme :SolidMasse moléculaire :372.38SAR125884 hydrochlorid (1116743-46-4(free base))
CAS :<p>SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).</p>Formule :C25H23FN8O2S2·HClDegré de pureté :97.95%Couleur et forme :SolidMasse moléculaire :587JNJ-38877605
CAS :<p>JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.</p>Formule :C19H13F2N7Degré de pureté :97.04% - 98.27%Couleur et forme :SolidMasse moléculaire :377.35Merestinib
CAS :<p>Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.</p>Formule :C30H22F2N6O3Degré de pureté :95% - 99.71%Couleur et forme :SolidMasse moléculaire :552.53MGCD-265 analog
CAS :<p>Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.</p>Formule :C26H20FN5O2S2Degré de pureté :98.06% - 98.68%Couleur et forme :SolidMasse moléculaire :517.6Savolitinib
CAS :<p>Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).</p>Formule :C17H15N9Degré de pureté :98.12%Couleur et forme :SolidMasse moléculaire :345.36Capmatinib xHCl
CAS :<p>Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50</p>Formule :C23H18ClFN6ODegré de pureté :98.62% - 99.81%Couleur et forme :SolidMasse moléculaire :448.89SRI 31215 TFA
CAS :<p>SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.</p>Formule :C27H34F3N5O3Degré de pureté :98.25% - 99.97%Couleur et forme :SolidMasse moléculaire :533.6Cabozantinib
CAS :<p>Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).</p>Formule :C28H24FN3O5Degré de pureté :99.68% - 99.88%Couleur et forme :SolidMasse moléculaire :501.51(Z)-Semaxinib
CAS :<p>(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for</p>Formule :C15H14N2ODegré de pureté :98.82% - ≥95%Couleur et forme :SolidMasse moléculaire :238.28Cabozantinib hydrochloride
CAS :<p>Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6</p>Formule :C28H25ClFN3O5Degré de pureté :99.97%Couleur et forme :SolidMasse moléculaire :537.96BAY-474
CAS :<p>BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe</p>Formule :C17H15N5Degré de pureté :98.98%Couleur et forme :SolidMasse moléculaire :289.33Afatinib
CAS :<p>Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.</p>Formule :C24H25ClFN5O3Degré de pureté :98.56% - 99.9%Couleur et forme :Off-White SolidMasse moléculaire :485.94Amivantamab
CAS :<p>Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.</p>Degré de pureté :97.24% (SEC-HPLC) - 99.74%Couleur et forme :LiquidMasse moléculaire :145.88 kDaFiclatuzumab
CAS :<p>Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.</p>Degré de pureté :95%Couleur et forme :LiquidDavutamig
CAS :<p>Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.</p>Degré de pureté :98%Couleur et forme :LiquidBafisontamab
CAS :<p>Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].</p>Couleur et forme :LiquidMAPK-IN-2
<p>MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell</p>Formule :C20H11Cl2N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.23SU11274
CAS :<p>SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.</p>Formule :C28H30ClN5O4SDegré de pureté :98.62% - 99.53%Couleur et forme :Orange PowderMasse moléculaire :568.09AMG-458
CAS :<p>AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.</p>Formule :C30H29N5O5Degré de pureté :99.91% - 99.98%Couleur et forme :SolidMasse moléculaire :539.58Glesatinib
CAS :<p>Glesatinib is an orally active and potent dual inhibitor of MET/SMO.</p>Formule :C31H27F2N5O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :619.7Dalmelitinib
CAS :<p>Dalmelitinib: oral c-Met kinase inhibitor, IC50 2.9 nM, disrupts MET, AKT, ERK in cancer cells, for NSCLC research.</p>Formule :C22H16FN7O2SCouleur et forme :SolidMasse moléculaire :461.47c-Met-IN-16
CAS :<p>c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .</p>Formule :C21H17F2N9OCouleur et forme :SolidMasse moléculaire :449.42ABN401
CAS :<p>ABN401: potent c-MET inhibitor (IC50: 10 nM), cytotoxic to MET-dependent cancers, blocks tumor c-MET phosphorylation, for cancer research.</p>Formule :C29H34N12OCouleur et forme :SolidMasse moléculaire :566.66AC-386
CAS :<p>AC-386, a potent c-Met inhibitor (IC50 7.42 nM), inhibits cancer cell growth and aids anti-cancer resistance study.</p>Formule :C35H34FN5O6Couleur et forme :SolidMasse moléculaire :639.67Tyrosine kinase-IN-4
CAS :<p>Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor [1].</p>Formule :C23H21N3O3Couleur et forme :SolidMasse moléculaire :387.43LCRF-0004
CAS :<p>LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.</p>Formule :C28H18F4N6O2SCouleur et forme :SolidMasse moléculaire :578.54c-Met-IN-13
CAS :<p>c-Met-IN-13: potent c-Met inhibitor (IC50 2.43 nM), exhibits anti-proliferative, cytotoxic effects; potential cancer therapy.</p>Formule :C30H28F2N2O6Couleur et forme :SolidMasse moléculaire :550.55SAR125844
CAS :<p>SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)</p>Formule :C25H23FN8O2S2Degré de pureté :98.73%Couleur et forme :SolidMasse moléculaire :550.63c-Met-IN-11
CAS :<p>c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).</p>Formule :C30H20F2N4O3Couleur et forme :SolidMasse moléculaire :522.5Glesatinib hydrochloride
CAS :<p>Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.</p>Formule :C31H28ClF2N5O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :656.16Axl-IN-8
CAS :<p>Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).</p>Formule :C31H29FN6O3Couleur et forme :SolidMasse moléculaire :552.6T-1840383
CAS :<p>T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.</p>Formule :C30H25ClFN5O4Couleur et forme :SolidMasse moléculaire :574MK-8033 hydrochloride
CAS :<p>MK-8033 hydrochloride is an oral ATP-competitive c-Met/Ron inhibitor (IC50: c-Met 1nM, Ron 7nM), used for various cancers including NSCLC.</p>Formule :C25H22ClN5O3SCouleur et forme :SolidMasse moléculaire :507.99Mifanertinib dimaleate
CAS :<p>Mifanertinib dimaleate is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Formule :C29H27ClF3N5O10Couleur et forme :SolidMasse moléculaire :698c-Met-IN-12
CAS :<p>c-Met-IN-12: potent c-Met/AXL/Mer/TYRO3 inhibitor, IC50=10.6 nM, oral, anti-tumor, scaffold for selectivity enhancement.</p>Formule :C34H29FN4O4Couleur et forme :SolidMasse moléculaire :576.62Boditrectinib
CAS :<p>Boditrectinib: potent TKI, anti-cancer, researches cancer, inflammation, neurodegeneration, infections.</p>Formule :C23H24F2N6OCouleur et forme :SolidMasse moléculaire :438.47Mifanertinib
CAS :<p>Mifanertinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Formule :C21H19ClF3N5O2Couleur et forme :SolidMasse moléculaire :465.86(R)-Afatinib
CAS :<p>(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.</p>Formule :C24H25ClFN5O3Couleur et forme :SolidMasse moléculaire :485.94Vabametkib
CAS :<p>Vabametkib: potent HGFR inhibitor, IC50 = 7 nM, halts Hs746T cell growth, used in cancer therapy.</p>Formule :C29H34N12OCouleur et forme :SolidMasse moléculaire :566.66SOMG-833 HCl
CAS :<p>SOMG-833 HCl is a selective inhibitor of c-MET. It acts by blocking c-MET dependent neoplastic effects and exerting antitumor activity.</p>Formule :C22H22F3N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :445.44met-kinase-in-2
CAS :<p>MET kinase-IN-2, a selective and potent MET kinase inhibitor, demonstrates oral bioavailability and exhibits an IC50 value of 7.4 nM.</p>Formule :C33H27FN4O4Couleur et forme :SolidMasse moléculaire :562.59Entacapone acid
CAS :<p>Entacapone acid (AG 1290) is a selective and reversible inhibitor of catechol-O-methyltransferase(COMT).</p>Formule :C10H6N2O6Degré de pureté :98.86%Couleur et forme :SolidMasse moléculaire :250.16SOMCL-863
CAS :<p>SOMCL-863 is a selective and orally bioavailable c-Met inhibitor. It shows antitumor activity both in vitro and in vivo.</p>Formule :C23H24F3N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :475.46BPI-9016M
CAS :<p>BPI-9016M, an oral c-Met/AXL inhibitor, curbs growth and spread of lung cancer.</p>Formule :C25H18F2N4O3Couleur et forme :SolidMasse moléculaire :460.43Terevalefim
CAS :<p>Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.</p>Formule :C9H8N2SDegré de pureté :99.8%Couleur et forme :SolidMasse moléculaire :176.24c-met-IN-1
CAS :<p>c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.</p>Formule :C35H37FN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :640.7OSI-296
CAS :<p>OSI-296: potent cMET/RON inhibitor (IC50: 42/200 nM), effective in tumor models, tolerable, oral, reduces bone tumor growth.</p>Formule :C21H19Cl2FN4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :465.3MET kinase-IN-3
CAS :<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Formule :C25H16ClF2N5O2Couleur et forme :SolidMasse moléculaire :491.88Adrixetinib
CAS :<p>Adrixetinib is an inhibitor of protein tyrosine kinase with antineoplastic activity .</p>Formule :C25H24F3N5O5Couleur et forme :SolidMasse moléculaire :531.48Emzeltrectinib
CAS :<p>Emzeltrectinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Formule :C17H15F3N6OCouleur et forme :SolidMasse moléculaire :376.34Resencatinib
CAS :<p>Resencatinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Formule :C30H29N7O3Couleur et forme :SolidMasse moléculaire :535.6Tyrosine kinase-IN-6
CAS :<p>Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].</p>Formule :C37H31F2N5O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :695.73MK-2461
CAS :<p>MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an</p>Formule :C24H25N5O5SDegré de pureté :95.41% - 99.53%Couleur et forme :SolidMasse moléculaire :495.55Zongertinib
CAS :<p>Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (</p>Formule :C29H29N9O2Degré de pureté :98.24%Couleur et forme :SolidMasse moléculaire :535.6EGFR-IN-8
CAS :<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Formule :C32H23ClF3N7O4Degré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :662.02c-Met-IN-2
CAS :<p>c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.</p>Formule :C24H21FN10ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :484.49SJF 8240
CAS :<p>c-MET degrader with foretinib linked to VHL ligand; reduces c-MET in 6h, hampers AKT, halts GTL16 cells (IC50=66.7nM), acts on exon-14-less c-MET.</p>Formule :C58H65F2N7O11SCouleur et forme :SolidMasse moléculaire :1106.25BMS-748730
CAS :<p>BMS-748730, also known as 4′-Hydroxy Dasatinib, is a Dasatinib metabolite.</p>Formule :C22H26ClN7O3SCouleur et forme :SolidMasse moléculaire :504.01D6808
<p>D6808: selective c-Met inhibitor, IC50=2.9 nM, induces apoptosis and cell cycle arrest, for NSCLC/gastric cancer research.</p>Formule :C30H25F3N6O2Couleur et forme :SolidMasse moléculaire :558.55c-Met-IN-26
CAS :<p>c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.</p>Formule :C24H19F2N9Couleur et forme :SolidMasse moléculaire :471.46TAM&Met-IN-1
CAS :<p>TAM&Met-IN-1 inhibits AXL, MER, TYRO3 with IC50s 6.1, 13.2, 21.6 nM, respectively, for cancer research.</p>Formule :C29H27F2N7O5Couleur et forme :SolidMasse moléculaire :591.57Zurletrectinib
CAS :<p>Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent.</p>Formule :C19H19F2N7O2Couleur et forme :SolidMasse moléculaire :415.4KRC-00715
CAS :<p>KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.</p>Formule :C25H25F3N8O3Couleur et forme :SolidMasse moléculaire :542.51Tyrosine kinase inhibitor
CAS :<p>Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.</p>Formule :C31H31FN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :586.61Canlitinib
CAS :<p>Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.</p>Formule :C33H31F2N3O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :619.61
